<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701346</url>
  </required_header>
  <id_info>
    <org_study_id>310475</org_study_id>
    <nct_id>NCT04701346</nct_id>
  </id_info>
  <brief_title>Sulfur Amino Acids, Energy Metabolism and Obesity</brief_title>
  <acronym>STAY</acronym>
  <official_title>Dietary Sulfur Amino Acid Restriction, Energy Metabolism and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to establish the effects of dietary sulfur amino acid&#xD;
      (SAA) restriction on body weight, body composition and energy expenditure in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dietary SAA restriction is an established model for increasing lifespan and improving&#xD;
      metabolic health in animal studies. Data from human studies are limited.&#xD;
&#xD;
      In this study the investigators will perform an 8-week dietary intervention with SAA&#xD;
      restriction to characterise the effects on several parameters related to metabolic health&#xD;
      including body weight, body composition, energy expenditure, lipid profile and gene&#xD;
      expression profiles in adipose tissue. The aim is to translate findings from previous animal&#xD;
      experiments to humans&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in resting energy expenditure</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Kilocalories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in substrate oxidation</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Respiratory quotient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body composition</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Fat mass (kilograms) and lean mass (kilograms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentrations of SAA and related intermediates and compounds</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Sulfite, thiosulfate, rhodanide, sulfate, total aminothiols (homocysteine, cysteine, glutathione gamma-glutamylcysteine, cysteinylglycine, cysteamine), and fractions of total cysteine, total glutathione and total homocysteine, cystathionine, lanthionine, homolanthionine, taurine hypotaurine, sarcosine, hydrogen sulfide, S-adenosylmethionine and S-adenosylhomocysteine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urine concentrations of SAA and related intermediates and compounds</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Including sulfite, thiosulfate, rhodanide, sulfate, total aminothiols (homocysteine, cysteine, glutathione gamma-glutamylcysteine, cysteinylglycine, cysteamine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in concentrations of plasma lipid profile</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Fatty acids, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, ApoA1, ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma makers of insulin sensitivity</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Concentrations of glucose and insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentrations of adipokines and appetite hormones</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Leptin, adiponectin, gastrin, ghrelin, cholecystokinin (CCK), glucagon-like peptide (GLP-1), oxyntomodulin, gastric inhibitory peptide (GIP), peptide YY (PYY), and pancreatic peptide (PP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>mRNA of proteins involved in SAA metabolism, lipid and energy metabolism in leucocytes and subcutaneous white adipose tissue samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin status</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Plasma concentrations of folate, B12 and methylmalonic acid (MMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers related to obesity and energy metabolism</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Untargeted analyses of plasma, serum and tissue concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fibroblast growth factor 21 (FGF21)</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrogen balance</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>24 h-urine urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut microbiota</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Sequencing of fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in short chain fatty acids</measure>
    <time_frame>At baseline, 4 and 8 weeks</time_frame>
    <description>Fecal concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Low SAA diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High SAA diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low SAA diet</intervention_name>
    <description>Diet with low content of methionine and cysteine</description>
    <arm_group_label>Low SAA diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High SAA diet</intervention_name>
    <description>Diet with high content of methionine and cysteine</description>
    <arm_group_label>High SAA diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy participants with overweight and obesity (BMI 27-35 kg/m2)&#xD;
&#xD;
          -  Waist circumference &gt; 80 cm for women and &gt; 94 cm for men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Presence of chronic disease&#xD;
&#xD;
          -  Established co-morbidities&#xD;
&#xD;
          -  Already on a vegan diet or have been the last month&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding the last 3 months&#xD;
&#xD;
          -  Unstable body weight the last 3 months&#xD;
&#xD;
          -  High intensity training &gt; 3 times weekly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjetil Dr Retterst√∏l, Prof. dr med</last_name>
    <role>Study Director</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Olsen, PhD</last_name>
    <phone>004722851525</phone>
    <email>thomas.olsen@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrine Vinknes, PhD</last_name>
    <phone>004722851525</phone>
    <email>kathrine.vinknes@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Clinical Nutrition, University of Oslo/Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Olsen, PhD</last_name>
      <email>thomas.olsen@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Kathrine J Vinknes, PhD</last_name>
      <email>kathrine.vinknes@medisin.uio.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Kathrine Vinknes</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Methionine</keyword>
  <keyword>Cysteine</keyword>
  <keyword>Sulfur amino acids</keyword>
  <keyword>Dietary intervention</keyword>
  <keyword>Plant-based diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>EU privacy regulations do not permit public sharing of IPD as long as the project is ongoing. Anonymized data can be shared after the project and biobank permissions end in 2030.&#xD;
The study protocol will be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

